---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-208965"
form_type: "8-K"
ticker: "BTMD"
cik: "0001819253"
company_name: "biote Corp."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:52:07.466073+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biote Q1 revenue $44.9M (-8.3% YoY); net income $2.7M vs $15.8M, hit by hormone pellet recall

## Summary
- Revenue $44.9M, down 8.3% YoY; net income $2.7M ($0.06 EPS) vs $15.8M ($0.37) in Q1 2025.
- Procedure revenue fell 13.2% to $31.3M due to voluntary recall of Asteria Health hormone pellets; supplements up 19.1% to $11.0M.
- Gross margin 68.9% vs 74.3% from higher replacement costs and reduced manufacturing efficiency at Asteria.
- Adjusted EBITDA $8.7M (19.4% margin); sales team expansion nearing target of 120 representatives.
- Management expects return to procedure growth in second half of 2026 after recall impact.

## SEC filing metadata
- accession: 0001193125-26-208965
- form_type: 8-K
- ticker: BTMD
- cik: 0001819253
- company_name: biote Corp.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819253/000119312526208965/0001193125-26-208965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819253/000119312526208965/btmd-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-208965
- JSON: https://secwatch.observer/filing/0001193125-26-208965.json
- Plain text: https://secwatch.observer/filing/0001193125-26-208965.txt

## Key facts
- Earnings Releases
  biote Corp. reported the first quarter ended March 31, 2026 results: revenue Revenue of $44.9 million, net income Net income of $2.7 million, EPS diluted earnings per share attributable to biote Corp. stockholders of $0.06.
  - Period: the first quarter ended March 31, 2026
  - Revenue: Revenue of $44.9 million
  - Net income: Net income of $2.7 million
  - EPS: diluted earnings per share attributable to biote Corp. stockholders of $0.06
  - Result: reported results
  source text: Results Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights • Revenue of $44.9 million • Gross profit margin of 68.9% • Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819253/000119312526208965/0001193125-26-208965-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.